Table 1. Hepatitis C virus treatment evolution.

This table provides an overview of the progression in drug treatment for the hepatitis C virus, depicting its development from the early stages to the current treatment regimen and future potential treatments. It showcases the remarkable evolution in managing this virus, from past breakthroughs to present advancements, and offers insights into the future.

SVR: sustained virological response.

Authors	Study design	Level of clinical evidence	Sample size	Drug(s)	SVR
Antiquated treatment(s)
Abonyi and Lakatos (2005) [19]	Non-randomized	II	650	Pegylated interferon alfa/ribavirin	66-87%
Current treatment(s)
Sulkowski et al. (2021) [28]	Randomized	I	1,128	Ledipasvir/sofosbuvir (arm 1), elbasvir/grazoprevir (arm 2)	95-99% (arm 1), 97% (arm 2)
Feld et al. (2015) [29]	Randomized with placebo	I	624	Sofosbuvir/velpatasvir	99%
Treatment(s) under development
Kong et al. (2021) [37]	Non-randomized	II	205	Seraprevir/sofosbuvir	98%
Gao et al. (2020) [38]	Non-randomized	II	371	Sofosbuvir/coblopasvir	97%
Wei et al. (2018) [39]	Randomized with placebo	I	155	Daclatasvir/asunaprevir	92%
Chua et al. (2021) [40]	Non-randomized	II	12	CDI31244/sofosbuvir/velpatasvir (shortened six-week trial)	67%